Om

Neovacs S.A. is a French biotechnology company specializing in therapeutic vaccines based on its proprietary Kinoid technology platform. The firm focuses on active immunotherapy solutions designed to treat autoimmune, inflammatory, allergy, and certain cancer-related conditions by inducing a targeted polyclonal immune response. Neovacs S.A. develops vaccine candidates that modulate harmful cytokines such as interferon alpha, IL-4, IL-13, and IgE, aiming to reduce immune system dysregulation in chronic diseases like lupus and severe allergies. Its current product portfolio centers on IFNα Kinoid for lupus and dermatomyositis, and IL-4/IL-13/IgE Kinoid for various allergic indications, supported by clinical and preclinical programs. In addition to its research and development activity, Neovacs S.A. also operates as an investor in innovative biotechnology and medical device companies, leveraging its sector expertise to support emerging healthcare technologies. Founded in 1993 and headquartered in Suresnes, France, Neovacs S.A. plays a specialized role in the healthcare market as a developer of immunotherapeutic vaccines targeting complex immune-mediated diseases.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I NEOVACS MED ENDAVU: Køb Neovacs ($0LW1) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Neovacs, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.